Search Technologies
Displaying 21 - 30 of 84 results
Researchers at the University of Maryland have created hundreds of innovations that are available for licensing. Our Discovery Portfolio contains an exciting mix of vaccines, drug targets, therapeutics, devices and cutting edge techniques that promise to make a quantifiable impact on human health and the environment.
Search by keyword:
-
Treating Optic Nerve Diseases with Neural Stem Cell Factors
Published Thursday, July 30, 2020The optic nerve lamina region (ONLR) is a small junctional region between the eye and optic nerve (ON), and is the primary damage site in age-related eye diseases, such as open angle glaucoma (OAG). Dr. Bernstein’s group at UMB discovered that the ONLR of both human and rodent contains an adult neural progenitor cell (NPC) niche, which...
Investigator(s): Steven Bernstein; Candace Kerr; Sally Temple
Categories: Therapeutics, Stem Cells
Keyword(s): Stem cell; eye disease; glaucoma
Docket: SB-2015-057
-
Targeting Protein Translation with Novel Small Molecules for Treating Pancreatic and Prostate Cancer
Published Sunday, June 2, 2019Medicinal chemists at UMB designed a family of novel small molecules which block key drivers of the protein translational complex by degrading MNK1/2 (i.e., mitogen-activated protein kinase (MAPK)-interacting kinase 1/2), thus inhibiting the activation of the eIF4E axis and inhibiting tumor growth. Lead...
Investigator(s): Vincent Njar, Puranik Purushottamachar, Andrew Kwegyir-Afful, Francis Murigi
Categories: Therapeutics, Small molecules
Keyword(s): oncology, Small molecule therapeutic
Docket: VN-2013-094
-
Inhibition of L-Plastin Activity in Osteoclasts to Reduce Bone Loss
Published Monday, March 11, 2019Osteoclasts (OCs) are specialized cell types that develop a focused microenvironment where bone matrix degradation can occur for the process of bone resorption or bone breakdown. Bone breakdown by osteoclasts requires the formation of tight sealing zone or ring in order for efficient focal bone breakdown to occur. L-plastin (LPL) is a...
Investigator(s): Meenakshi Chellaiah
Categories: Therapeutics, Biologics
Keyword(s): osteoporosis bone loss peptide
Docket: MC-2015-066
-
Analogs of GHB Lacking GABAergic Activity
Published Monday, February 11, 2019The present invention relates to esthers of 3-hydroxyphenyacetic acid and their use to treat narcolepsy and other sleep disorders. Gamma-hydroxybutyric acid (GHB) is a known agonist for the GHB receptor. Unfortunately it also acts at GABA receptors directly and through its metabolization into alpha aminobutyric acid (GABA). As a result,...
Investigator(s): Andrew Coop, Maharaj Ticku, Charles France
Categories: Therapeutics, Small molecules
Keyword(s): narcolepsy, cataplexy, sleep disorderes
Docket: AC-2006-050
-
Monoclonal antibodies inhibiting fibrin-VLDL receptor-dependent inflammation
Published Tuesday, January 22, 2019Fibrin is a fibrous, non-globular protein involved in blood clotting and promotes leukocyte transmigration through its interaction with the endothelial cell receptor, the very low density lipoprotein (VLDL) receptor. The VLDL receptor is predominantly expressed in the heart, skeletal muscle, fat, brain and macrophages and involved in neural...
Investigator(s): Leonid Medved, Sergiy Yakovlev, Dudley Strickland
Categories: Therapeutics, Biologics
Keyword(s): Cardiology, antibody, inflammation, fibrin
Docket: LM-2016-049
-
Selective RARγ Ligand-loaded Nanoparticles for Manipulation of Targeted Bone Growth
Published Wednesday, June 27, 2018Imbalance in bone length, caused by congenital conditions or fractures, can result in progressive deformity and physical problems. To date, the only way to adjust these bone length problems are surgical procedures. UMB researchers have identified a nuclear retinoid receptor, RARγ, which controls the rate of transition from cartilage to...
Investigator(s): Masahiro Iwamoto, Michael Chorny
Categories: Therapeutics, Other
Keyword(s): Orthopedics, Therapeutics Drug Delivery System
Docket: MI-2017-124
-
A Method for Monitoring Cancer and for Regulation of Semaphorin 4D to Improve Cancer Immunotherapy Regimens
Published Monday, May 14, 2018The efficacy of current cancer immunotherapies has been limited by the response of immunosuppressive elements such as myeloid derived suppressor cells (MDSC) and T regulatory cells. Understanding the mechanism behind the suppression of antitumor immunity, and finding ways to revert it, should lead to improved cancer immunotherapy outcomes....
Investigator(s): Rania Younis
Categories: Diagnostics, Biomarker, Therapeutics
Keyword(s): Semaphorin 4D, immunotherapy, oncology, head and neck, cancer
Docket: RY-2015-129
-
Proton Arc Therapy with Modulating Proton Energies
Published Tuesday, May 1, 2018Proton radiation therapy is a type of external beam radiotherapy that uses the energy distribution of protons to irradiate unwanted and diseased tissues. The proton beam can be directed and deposited by a physician in a designated 3-dimensional tissue volume with greater control and accuracy than traditional radiation...
Investigator(s): Byong Yong Yi, Ulrich Langner, Warren D’Souza
Categories: Devices, Imaging devices, Therapeutics
Keyword(s): Radiation Oncology, imaging
Docket: BY-2017-075
-
Small Molecule Lipid II Inhibitors
Published Friday, February 16, 2018Drug resistance in microorganisms is an urgent and growing concern as more and more microorganisms are found with resistance to commonly used treatments. For bacterial infections alone, approximately 2 million people are infected a year and 23,000 deaths can be directly correlated to drug-resistant bacteria (CDC). There is an urgent need for...
Investigator(s): Eric DeLeeuw, Jamal Chauhan, Steven Fletcher, Alexander MacKerell
Categories: Therapeutics, Small molecules
Keyword(s): Anti-infective
Docket: ED-2016-042
-
Hyper-glycosylated Antibodies with Selective Fc Receptor Binding
Published Friday, February 16, 2018This technology is a set of hyper-glycosylated antibodies that have been modified in the Fc domain of the antibody to either enhance or reduce the affinity of the Fc region to the Fc γ...
Investigator(s): Eric Sundberg, Beatriz Trastoy-Bello
Categories: Therapeutics, Biologics
Keyword(s): Immunology
Docket: ES-2013-128